Leerink Partners analyst David Risinger has reiterated their bullish stance on ORKA stock, giving a Buy rating on July 21.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
David Risinger’s rating is based on several compelling factors. Firstly, Oruka Therapeutics has received FDA clearance to initiate a Phase 2a trial for ORKA-001, an ultralong-acting antibody targeting IL-23p19, which shows promise for annual dosing in treating moderate-to-severe plaque psoriasis. This innovative approach could potentially redefine the standard of care by offering once-yearly dosing and higher clearance rates, which are significant advantages over existing treatments.
Additionally, the valuation of Oruka’s shares is considered attractive, with a current stock price significantly lower than the price target set by the firm. The company’s robust financial position, with substantial net cash and a promising pipeline that includes ORKA-002 for skin disorders, further supports the Buy rating. These factors combined suggest a strong potential for growth and value appreciation in Oruka’s stock.
In another report released on July 21, Stifel Nicolaus also reiterated a Buy rating on the stock with a $47.00 price target.
ORKA’s price has also changed slightly for the past six months – from $12.980 to $13.770, which is a 6.09% increase.